{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T14:42:10Z","timestamp":1788705730246,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","neuropeptidesjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropeptides"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.npep.2016.06.003","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T21:52:00Z","timestamp":1466718720000},"page":"39-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn's disease in rats"],"prefix":"10.1016","volume":"59","author":[{"given":"Dina Ibrahim","family":"Tawfik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afaf Sayed","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedayat Mahmoud","family":"Tolba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna O.","family":"Abdel-Salam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.npep.2016.06.003_bb0005","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1136\/gut.41.6.763","article-title":"Vascular anatomy defines sites of indomethacin-induced ulceration along the mesenteric margin","volume":"41","author":"Anthony","year":"1997","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.npep.2016.06.003_bb0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1365-2036.2000.00694.x","article-title":"Similarities between ileal Crohn's disease and indomethacin experimental jejunal ulcers in the rat","volume":"14","author":"Anthony","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.npep.2016.06.003_bb0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0143-4179(03)00045-3","article-title":"Expression and G-protein coupling of mu-opioid receptors in the spinal cord and dorsal root ganglia of polyarthritic rats","volume":"37","author":"Ballet","year":"2003","journal-title":"Neuropeptides"},{"key":"10.1016\/j.npep.2016.06.003_bb0020","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0006-2952(02)01616-7","article-title":"Indomethacin-induced free radical-mediated changes in the intestinal brush border membranes","volume":"65","author":"Basivireddy","year":"2003","journal-title":"Biochem. Pharmacol."},{"issue":"9853","key":"10.1016\/j.npep.2016.06.003_bb0025","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn's disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.npep.2016.06.003_bb0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.mehy.2008.06.048","article-title":"Low-dose naltrexone for disease prevention and quality of life","volume":"72","author":"Brown","year":"2008","journal-title":"Med. Hypotheses"},{"issue":"6","key":"10.1016\/j.npep.2016.06.003_bb0035","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2011.02.046","article-title":"Recent insights into the genetics of inflammatory bowel disease","volume":"140","author":"Cho","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.npep.2016.06.003_bb0040","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.0105-2896.2005.00293.x","article-title":"Defects in mucosal immunity leading to Crohn's disease","volume":"206","author":"Cobrin","year":"2005","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.npep.2016.06.003_bb0045","first-page":"238","article-title":"Clinicopathologic study of dextran sulfate sodium experimental murine colitis","volume":"69","author":"Cooper","year":"1993","journal-title":"Lab. Investig."},{"key":"10.1016\/j.npep.2016.06.003_bb0050","first-page":"23","article-title":"Low dose naltrexone for induction of remission in Crohn's disease","volume":"28","author":"Dan Segal","year":"2013","journal-title":"Funct. Bowel Disord."},{"issue":"8","key":"10.1016\/j.npep.2016.06.003_bb0055","first-page":"56","article-title":"An open trial of naltrexone in the treatment of depersonalization disorder","volume":"23","author":"Daphne","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.npep.2016.06.003_bb0060","series-title":"Basic and Clinical Biostatistics","author":"Dawson","year":"2001"},{"key":"10.1016\/j.npep.2016.06.003_bb0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3923\/rjmp.2010.141.148","article-title":"Effect of Emblica officinalis methanolic fruit extract on indomethacin induced enterocolitis in rats","volume":"4","author":"Deshmukh","year":"2010","journal-title":"Res. J. Med. Plant"},{"key":"10.1016\/j.npep.2016.06.003_bb0070","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1097\/MCG.0b013e3181662c90","article-title":"Innate immunity in Crohn's disease","volume":"42","author":"Dessein","year":"2008","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.npep.2016.06.003_bb0075","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/gut.2009.179994","article-title":"A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease","volume":"59","author":"Dotan","year":"2010","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.npep.2016.06.003_bb0080","first-page":"707","article-title":"Management of Crohn's disease. A practical approach","volume":"68","author":"Doug","year":"2003","journal-title":"Am. Fam. Physician"},{"issue":"7","key":"10.1016\/j.npep.2016.06.003_bb0085","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1053\/j.gastro.2007.03.104","article-title":"Monoclonal anti \u2013 Interleukin 23 reverses active colitis in a T cell \u2013 Mediated model in mice","volume":"132","author":"Elson","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.npep.2016.06.003_bb0090","first-page":"1229","article-title":"Small intestine","volume":"7","author":"Evers","year":"1999","journal-title":"Princ. Surg."},{"issue":"7","key":"10.1016\/j.npep.2016.06.003_bb0095","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1023\/A:1026620322859","article-title":"Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and ultrastructural aspects","volume":"44","author":"Gaudio","year":"1999","journal-title":"Dig. Dis. Sci."},{"issue":"4\u20139243","key":"10.1016\/j.npep.2016.06.003_bb0100","first-page":"276","article-title":"Investigating the protective effect of Solanum melongena","volume":"1","author":"Gul","year":"2011","journal-title":"Int. Peer Rev. J."},{"issue":"2","key":"10.1016\/j.npep.2016.06.003_bb0105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0024-3205(96)00597-8","article-title":"Alcohol induces formation of morphine precursors in the striatum of rats","volume":"60","author":"Haber","year":"1997","journal-title":"Life Sci."},{"key":"10.1016\/j.npep.2016.06.003_bb0110","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1572-0241.2001.03671.x","article-title":"Management of Crohn's disease in adults","volume":"96","author":"Hanauer","year":"2001","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.npep.2016.06.003_bb0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.regpep.2009.03.012","article-title":"Opioid receptors in the gastrointestinal tract","volume":"155","author":"Holzer","year":"2009","journal-title":"Regul. Pept."},{"issue":"4","key":"10.1016\/j.npep.2016.06.003_bb0120","first-page":"248","article-title":"Diagnosis and treatment of Crohn's disease in children","volume":"45","author":"Huang","year":"2007","journal-title":"Clin. Experience"},{"issue":"9","key":"10.1016\/j.npep.2016.06.003_bb0125","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2004.060228","article-title":"Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease","volume":"54","author":"Israeli","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.npep.2016.06.003_bb0130","first-page":"4","article-title":"Opioid receptors and their ligands","volume":"1","author":"Janecka","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"issue":"4","key":"10.1016\/j.npep.2016.06.003_bb0135","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","article-title":"The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain","volume":"33","author":"Jarred","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.npep.2016.06.003_bb0140","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.cgh.2008.06.010","article-title":"Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease","volume":"6","author":"Jones","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.npep.2016.06.003_bb0145","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/01.MIB.0000160806.53858.55","article-title":"Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine and mesalamine in rabbit distal ileum","volume":"11","author":"Keri","year":"2005","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.npep.2016.06.003_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008870","article-title":"Aminosalicylates for induction of remission or response in Crohn's disease","volume":"8870-9","author":"Lim","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.npep.2016.06.003_bb0155","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.npep.2016.06.003_bb0160","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.npep.2007.06.001","article-title":"Targeting of opioid-producing leukocytes for pain control","volume":"41","author":"Machelska","year":"2007","journal-title":"Neuropeptides"},{"issue":"24","key":"10.1016\/j.npep.2016.06.003_bb0165","first-page":"3","article-title":"Management of inflammatory bowel disease with infliximab and other anti-tumor","volume":"4","author":"Magro","year":"2010","journal-title":"Bio Drugs"},{"issue":"4","key":"10.1016\/j.npep.2016.06.003_bb0170","first-page":"787","article-title":"Neuropsychiatric symptoms related to interferon alpha","volume":"40","author":"Ma\u0142yszczak","year":"2006","journal-title":"Psychiatr. Pol."},{"issue":"2","key":"10.1016\/j.npep.2016.06.003_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1300\/J069v25n02_01","article-title":"Antagonist treatment of opioid withdrawal translational low dose approach","volume":"25","author":"Mannelli","year":"2006","journal-title":"J. Addict. Dis."},{"issue":"1","key":"10.1016\/j.npep.2016.06.003_bb0180","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12016-009-8133-2","article-title":"Crohn's disease: an immune deficiency state","volume":"38","author":"Marks","year":"2010","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.npep.2016.06.003_bb0185","first-page":"182","article-title":"The opioid antagonist naltrexone improves murine inflammatory bowel disease","author":"Matters","year":"2008","journal-title":"J. Immunotoxicol."},{"issue":"654","key":"10.1016\/j.npep.2016.06.003_bb0190","first-page":"345","article-title":"Acute and chronic colitis in C57BL\/6 mice","volume":"2","author":"Melgar","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.npep.2016.06.003_bb0195","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/bja\/aeg219","article-title":"Effects of endogenous and synthetic opioid peptides on neutrophil function in vitro","volume":"91","author":"Menzebach","year":"2003","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.npep.2016.06.003_bb0200","first-page":"133","article-title":"Oral naltrexone maintenance treatment for opioid dependence","volume":"4","author":"Minozzi","year":"2011","journal-title":"Syst. Rev."},{"issue":"5","key":"10.1016\/j.npep.2016.06.003_bb0205","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.2010.224154","article-title":"Guidelines for the management of inflammatory bowel disease in adults","volume":"60","author":"Mowat","year":"2011","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.npep.2016.06.003_bb0210","first-page":"189","article-title":"Impact of low dose naltrexone (LDN) on antiretroviral therapy (ART) treated HIV+ adults in Mali: a single blind randomized clinical trial","volume":"3","author":"Oumar","year":"2011","journal-title":"J. AIDS HIV Res."},{"issue":"6","key":"10.1016\/j.npep.2016.06.003_bb0215","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/gut.2005.080887","article-title":"Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation","volume":"55","author":"Philippe","year":"2006","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.npep.2016.06.003_bb0220","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2362.2005.01489.x","article-title":"Indomethacin-induced ileitis is associated with tensiometric, vascular and oxidative changes in the experimental rat model","volume":"35","author":"Piepoli","year":"2005","journal-title":"Eur. J. Clin. Investig."},{"issue":"12","key":"10.1016\/j.npep.2016.06.003_bb0225","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1111\/j.1572-0241.2000.03361.x","article-title":"Identification of a prodromal period in Crohn's disease but not ulcerative colitis","volume":"95","author":"Pimentel","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.npep.2016.06.003_bb0230","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1365-2036.2001.01009.x","article-title":"Interleukin-8 increases acetylcholine response of rat intestinal segments","volume":"15","author":"Plattner","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.npep.2016.06.003_bb0235","first-page":"672","article-title":"Effect of combination of thalidomide and salfasalazine in experimentally induced inflammatory bowel disease in rats","volume":"49","author":"Prakash","year":"2011","journal-title":"Indian J. Exp. Biol."},{"key":"10.1016\/j.npep.2016.06.003_bb0240","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/00365520510015629","article-title":"IL-1 receptor antagonist (IL- 1Ra) gene polymerphism in patient with inflammatory bowel disease in India","volume":"40","author":"Rama","year":"2005","journal-title":"Scand. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.npep.2016.06.003_bb0245","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.npep.2016.06.003_bb0250","first-page":"234","volume":"Vol. 159","author":"Rumack","year":"2014"},{"key":"10.1016\/j.npep.2016.06.003_bb0255","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gie.2005.08.011","article-title":"Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease","volume":"63","author":"Rutgeerts","year":"2006","journal-title":"Gastrointest. Endosc."},{"issue":"2","key":"10.1016\/j.npep.2016.06.003_bb0260","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cellsig.2005.08.005","article-title":"Opioid elevation of intracellular free calcium: possible mechanisms and physiological relevance","volume":"18","author":"Samways","year":"2006","journal-title":"Cell. Signal."},{"key":"10.1016\/j.npep.2016.06.003_bb0265","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2036.2003.01408.x","article-title":"The pharmacokinetic profiles of oral mesalazine formulations used in the management of ulcerative colitis","volume":"17","author":"Sandborn","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.npep.2016.06.003_bb0270","first-page":"234","article-title":"Low dose naltrexone for induction of remission in Crohn's disease","volume":"2","author":"Segal","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.npep.2016.06.003_bb0275","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.jcp.0000087502.38434.6c","article-title":"Antagonists, inverse agonists, and protagonists","volume":"23","author":"Shader","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.npep.2016.06.003_bb0280","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1572-0241.2007.01045.x","article-title":"Low-dose naltrexone therapy improves active Crohn's disease","volume":"102","author":"Smith","year":"2007","journal-title":"Am. J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.npep.2016.06.003_bb0285","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s10620-011-1653-7","article-title":"Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial","volume":"56","author":"Smith","year":"2011","journal-title":"Dig. Dis. Sci."},{"issue":"4","key":"10.1016\/j.npep.2016.06.003_bb0290","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MCG.0b013e3182702f2b","article-title":"Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study","volume":"47","author":"Smith","year":"2013","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.npep.2016.06.003_bb0295","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/gut.43.3.365","article-title":"Colman kallikrein-kininogen system activation and bradykinin (B2) receptors in indomethacin induced enterocolitis in genetically susceptible Lewis rats","volume":"43","author":"Stadnicki","year":"1998","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.npep.2016.06.003_bb0300","first-page":"445","article-title":"Low dose naltrexone","volume":"2","author":"Steven","year":"2010","journal-title":"Sci.-Based Med."},{"key":"10.1016\/j.npep.2016.06.003_bb0305","first-page":"402","article-title":"Methionine-enkephalin stimulates hydrogen peroxide and nitric oxide production in rat peritoneal macrophages interaction of mu, delta and kappa opioid receptors","volume":"392","author":"Vujic","year":"2004","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.npep.2016.06.003_bb0310","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2982.2008.01225.x","article-title":"Afferent nerve sensitivity is decreased by an iNOS dependent mechanism during indomethacin-induced inflammation in the murine jejunum in vitro","volume":"21","author":"Xue","year":"2009","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.npep.2016.06.003_bb0315","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/BF00920471","article-title":"Mechanisms of acute and chronic intestinal inflammation induced by indomethacin","volume":"17","author":"Yamada","year":"1993","journal-title":"Inflammation"},{"issue":"4","key":"10.1016\/j.npep.2016.06.003_bb0320","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","article-title":"The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain","volume":"33","author":"Younger","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.npep.2016.06.003_bb0325","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.npep.2005.07.001","article-title":"Opioids and differentiation in human cancer cells","volume":"39","author":"Zagon","year":"2005","journal-title":"Neuropeptides"}],"container-title":["Neuropeptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417916300348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417916300348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:09:35Z","timestamp":1568074175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0143417916300348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":65,"alternative-id":["S0143417916300348"],"URL":"https:\/\/doi.org\/10.1016\/j.npep.2016.06.003","relation":{},"ISSN":["0143-4179"],"issn-type":[{"value":"0143-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn's disease in rats","name":"articletitle","label":"Article Title"},{"value":"Neuropeptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.npep.2016.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}